Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Short-term Acipimox decreases the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport
Autore:
Dullaart, RPF; van Tol, A;
Indirizzi:
Univ Groningen Hosp, Dept Endocrinol, NL-9700 RB Groningen, Netherlands Univ Groningen Hosp Groningen Netherlands NL-9700 RB ningen, Netherlands Erasmus Univ, Dept Biochem, Cardiovasc Res Inst, NL-3000 DR Rotterdam, Netherlands Erasmus Univ Rotterdam Netherlands NL-3000 DR DR Rotterdam, Netherlands
Titolo Testata:
DIABETIC MEDICINE
fascicolo: 6, volume: 18, anno: 2001,
pagine: 509 - 513
SICI:
0742-3071(200106)18:6<509:SADTAO>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHOSPHOLIPID TRANSFER PROTEIN; HIGH-DENSITY-LIPOPROTEIN; ESTER TRANSFER PROTEIN; APOLIPOPROTEIN A-I; SERUM-LIPIDS; INSULIN; MELLITUS; HYPERTRIGLYCERIDEMIA; HYPERLIPOPROTEINEMIA; PARTICLES;
Keywords:
Acipimox; cellular cholesterol efflux; phospholipid transfer protein; pre-beta high density lipoproteins; Type 2 diabetes mellitus;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Dullaart, RPF Univ Groningen Hosp, Dept Endocrinol, POB 30-001, NL-9700 RBGroningen, Netherlands Univ Groningen Hosp POB 30-001 Groningen Netherlands NL-9700 RB
Citazione:
R.P.F. Dullaart e A. van Tol, "Short-term Acipimox decreases the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport", DIABET MED, 18(6), 2001, pp. 509-513

Abstract

Aims To evaluate the effect of short-term administration of the anti-lipolytic agent, Acipimox, on the ability of plasma to stimulate cellular cholesterol removal, which represents one of the first steps in the anti-atherogenic process of reverse cholesterol transport. Methods Eight male Type 2 diabetic patients and eight healthy subjects were studied after a 12-h fast at baseline, after 24 h of Acipimox administration, 250 mg every 4 h, and again after 1 week (recovery). Plasma lipids, apolipoprotein AI, phospholipid transfer protein (PLTP) activity, pre-beta high-density lipoproteins (HDL) in incubated plasma and efflux of radiolabelled cholesterol from Fu5AH rat hepatoma cells to plasma were measured at each time point. Results Acipimox lowered plasma triglycerides in diabetic patients (P = 0.001) and healthy subjects (P = 0.002), whereas plasma non-esterified fatty acids were decreased in diabetic patients (P = 0.001) compared with the averaged values at baseline and recovery. Acipimox decreased HDL cholesterol in healthy subjects (P = 0.007) and plasma apolipoprotein AI in both groups (P = 0.001 for diabetic patients; P = 0.008 for healthy subjects). Not onlyplasma PLTP activity (P = 0.001 for diabetic patients; P = 0.01 for healthy subjects), but also pre-beta HDL in incubated plasma (P = 0.001 for diabetic patients; P = 0.03 for healthy subjects) and cellular cholesterol efflux to plasma (P = 0.04 for diabetic patients; P = 0.005 for healthy subjects) were lowered by Acipimox in both groups. Conclusions Short-term Acipimox administration impairs the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellularcholesterol efflux, in conjunction with alterations in HDL parameters and in PLTP activity. If the impairment of cellular cholesterol efflux to plasma is sustained with long-term treatment, this potentially adverse effect should be considered when treating diabetic dyslipidaemia with Acipimox.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 04:48:38